NEW AGENT FOR THE PREVENTION OF OSTEOPOROSIS, AND CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN
PD Delmas, B. Mitlak(Eli Lilly (United States)), N. H. Bjarnason(Center for Clinical & Basic Research)
Cited by 0
Related Papers
Low Body Mass Index Is an Important Risk Factor for Low Bone Mass and Increased Bone Loss in Early Postmenopausal Women
|Journal of Bone and Mineral Research|1999|455
Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy
|Osteoporosis International|2004|320
Evaluation of vertebral fracture assessment by dual X-ray absorptiometry in a multicenter setting
|Osteoporosis International|2008|103
The effect of 2 and 3 years of Raloxifene on vertebral and non-vertebral fractures in postmenopausal women with osteoporosis
|ORBi (University of Liège)|1998|21
Parathyroid hormone as a therapeutic agent
|Current Opinion in Pharmacology|2002|20